A Pilot Study to Assess the Combination of Stereotactic Body Radiation Therapy and CDX-1127 in Modulating Local and Systemic T-cell Responses Against Prostate Cancer

Trial Profile

A Pilot Study to Assess the Combination of Stereotactic Body Radiation Therapy and CDX-1127 in Modulating Local and Systemic T-cell Responses Against Prostate Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 May 2017

At a glance

  • Drugs Varlilumab (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms Prostate-04
  • Sponsors Celldex Therapeutics Inc
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Nov 2016 Status changed from recruiting to discontinued.
    • 17 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top